Cold chain and virus‐free oral polio booster vaccine made in lettuce chloroplasts confers protection against all three poliovirus serotypes

Daniell, Henry; Rai, Vineeta; Xiao, Yuhong

doi:10.1111/pbi.13060

Cited by 57 publications

(52 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent advancements in the plant expression strategies, especially the development of transient expression system or viral vectors, resulted in a huge increase in the protein yield that makes this plant host system, a promising system for the production of various biopharmaceutical proteins [16]. Several reports in the last two decades have enough evidence to prove that the plant produced biopharmaceuticals are as effective as the mammalian cell-based proteins and also elicit potent neutralizing antibodies, or shown therapeutic effects against the particular pathogen or infection [17][18][19]. The use of plants for the production of recombinant proteins and biopharmaceuticals has been gaining importance since the plant produced biologic taliglucerase alfa has been commercialized in 2012 against Gaucher's disease that proclaimed a new era for plant made biopharmaceutical and triggered the innovation in the field of biopharmaceuticals [20].…”

Section: Perspectives On Biopharmaceuticals Developmentmentioning

confidence: 99%

Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development

2020

View full text Add to dashboard Cite

Novel Coronavirus (2019-nCoV) is an emerging pathogen that was first identified in Wuhan, China in late December 2019. This virus is responsible for the ongoing outbreak that causes severe respiratory illness and pneumonia-like infection in humans. Due to the increasing number of cases in China and outside China, the WHO declared coronavirus as a global health emergency. Nearly 35,000 cases were reported and at least 24 other countries or territories have reported coronavirus cases as early on as February. Inter-human transmission was reported in a few countries, including the United States. Neither an effective anti-viral nor a vaccine is currently available to treat this infection. As the virus is a newly emerging pathogen, many questions remain unanswered regarding the virus's reservoirs, pathogenesis, transmissibility, and much more is unknown. The collaborative efforts of researchers are needed to fill the knowledge gaps about this new virus, to develop the proper diagnostic tools, and effective treatment to combat this infection. Recent advancements in plant biotechnology proved that plants have the ability to produce vaccines or biopharmaceuticals rapidly in a short time. In this review, the outbreak of 2019-nCoV in China, the need for rapid vaccine development, and the potential of a plant system for biopharmaceutical development are discussed.

show abstract

Section: Perspectives On Biopharmaceuticals Developmentmentioning

confidence: 99%

Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development

2020

View full text Add to dashboard Cite

show abstract

“…VLPs have been generated from a large number of anthroponotic and zoonotic viruses [32], [35]- [37]. They are composed of one or more structural or capsid proteins capable of self-assembly into virion-like morphological structures.…”

Section: Structure Of the Vlpsmentioning

confidence: 99%

“…Recently, there has been described viral nanoparticles (VNPs) and VLPs derived from plant viruses [35].…”

Section: Structure Of the Vlpsmentioning

confidence: 99%

See 1 more Smart Citation

Virus-Like Particles: Applications in Reverse Vaccinology

A¹,

Pastorini²,

Borio³

et al. 2020

Preprint

View full text Add to dashboard Cite

Vaccination has been one of the most successful and the most significant scientific advances in human health and life expectancy all around the globe. The World Health Organization considers that immunization should be recognized as the main component of human health right, due to the fact that vaccination prevents 2.5 million deaths annually (World Health Organization, 2011). The most successful vaccines have been developed using conventional methods that follow the paradigm established by Pasteur: "to isolate, inactivate and inject" the pathogen microorganism and mimic a natural infection. Recently, metagenomics have played an important role in the discovery of new immunogens for vaccine design and the selection of antigens based on genomic information. The main approach that has used this strategy has been called "reverse vaccinology". This promising and arising field allows the screening of the entire potential antigenic repertoire of an organism using predictive bioinformatic tools. Once the antigenic protein or proteins have been selected, they are expressed and purified using molecular cloning and in vitro expression techniques. Following the in vitro production step, they are probed in animal models to evaluate the in vivo protective strength of the immune response. The main aim of this in vivo approach is to evaluate the ability of the immune response to eliminate or neutralize the pathogen at the time of infection. Those antigens capable of generate a specific immune response with neutralizing activity for natural infections are the best candidate vaccines. In this review we summarize the evolution of vaccinology since its inception, with special emphasis on the development of VLPs as vaccine platforms and their future in preventive medicine and we introduce a new recombinant platform for antigen presentation based on Junin virus VLPs (JUNV-VLPs).

show abstract

“…Plant-derived vaccines are suitable for booster vaccines, specifically where the number of doses is needed over long periods to induce and maintain immunity, in population where reinfection occurs due to environmental exposure. Proof-of-concept reports described in mice have indicated the efficient use of plants cell in heterologous prime-boost strategies (Daniell, 2019;Daniell et al, 2018;Lakshmi et al, 2013;Meador et al, 2017). However, in the absence of such priming, plant cells are not suitable for vaccination against infectious diseases (Chan et al, 2016;Daniell, 2019;Xiao and Daniell, 2017).…”

Section: Plant-based Candidate Vaccines Against Hivmentioning

confidence: 99%

The potential of plant systems to break the HIV‐TB link

Habibi

Daniell

Soccol

et al. 2019

Plant Biotechnology Journal

Self Cite

View full text Add to dashboard Cite

Summary Tuberculosis (TB) and human immunodeficiency virus (HIV) can place a major burden on healthcare systems and constitute the main challenges of diagnostic and therapeutic programmes. Infection with HIV is the most common cause of Mycobacterium tuberculosis (Mtb), which can accelerate the risk of latent TB reactivation by 20‐fold. Similarly, TB is considered the most relevant factor predisposing individuals to HIV infection. Thus, both pathogens can augment one another in a synergetic manner, accelerating the failure of immunological functions and resulting in subsequent death in the absence of treatment. Synergistic approaches involving the treatment of HIV as a tool to combat TB and vice versa are thus required in regions with a high burden of HIV and TB infection. In this context, plant systems are considered a promising approach for combatting HIV and TB in a resource‐limited setting because plant‐made drugs can be produced efficiently and inexpensively in developing countries and could be shared by the available agricultural infrastructure without the expensive requirement needed for cold chain storage and transportation. Moreover, the use of natural products from medicinal plants can eliminate the concerns associated with antiretroviral therapy (ART) and anti‐TB therapy (ATT), including drug interactions, drug‐related toxicity and multidrug resistance. In this review, we highlight the potential of plant system as a promising approach for the production of relevant pharmaceuticals for HIV and TB treatment. However, in the cases of HIV and TB, none of the plant‐made pharmaceuticals have been approved for clinical use. Limitations in reaching these goals are discussed.

show abstract

Cold chain and virus‐free oral polio booster vaccine made in lettuce chloroplasts confers protection against all three poliovirus serotypes

Cited by 57 publications

References 52 publications

Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development

Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development

Virus-Like Particles: Applications in Reverse Vaccinology

The potential of plant systems to break the HIV‐TB link

Contact Info

Product

Resources

About